Frontlight ResearchEarly access
Neuroendocrine tumours trials in France
30 of 41 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Le Kremlin-Bicêtre, Lyon, Marseille, Paris, Strasbourg, Villejuif
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - No phaseTaking peopleClinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
- Where
- Bordeaux, Marseille, Montpellier, Toulouse
- Age
- 18 years and over
- People
- 350
- Run by
- Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04104529 - Phase 1/2Not yet taking people in FranceDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Lyon, Marseille, Villejuif
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00 - Phase 3Taking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Angers, Limoges Cedex I, Strasbourg Cedex 2, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - Phase 3Taking peopleDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
- Where
- Clichy, Dijon, Lyon Cedex 03, Marseille, Pessac, Rennes Cedex, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 390 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00 - Phase 2/3Taking peopleZanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Where
- Caen, Clichy, Lille, Lyon, Marseille, Montpellier, Nantes, Rennes, Strasbourg, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 440 worldwide
- Run by
- Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00 - Phase 1Not yet taking people in FrancePhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Lyon, Marseille, Toulouse Cedex 9
- Age
- 18 years to 100 years
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - Phase 3Taking peopleRandomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
- Where
- Caen, Clichy, Dijon, Lille, Lyon, Marseille, Paris, Rennes, Villejuif
- Age
- 18 years and over
- People
- 166 worldwide
- Run by
- Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT06878664 · EU 2024-517921-14-00 - Phase 3Taking peopleStudy to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
- Where
- Bordeaux, Bron, Clichy, Lyon Cedex 03, Marseille, Montpellier Cedex 5, Nantes, Pessac, Pierre-Bénite, Talence, Toulouse
- Age
- 12 years to 100 years
- People
- 240 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00 - Phase 2Taking peopleFIRST-NEC - A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab (MEDI 4736) with etoposide and platinum as first line treatment in patients with large-cell neuroendocrine carcinomas (LCNECs) of the lung.
- Where
- Aix En Provence, Amiens Cedex 1, Brest Cedex 2, Caen Cedex 5, Créteil, Grenoble Cedex 9, Lille, Limoges Cedex 1, Lorient, Lyon, Lyon Cedex 02, Marseille, Meaux, Mulhouse, Nice, Paris, Paris Cedex 20, Pringy Cedex, Quimper Cedex, Rennes, Strasbourg, Strasbourg Cedex, Toulon Cedex 9, Villefranche Sur Saone Cedex
- Age
- 18 years and over
- People
- 80
- Run by
- Centre Leon Berard
See details and how to join2023-506590-35-00 - No phaseTaking peopleSuperb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy
- Where
- Lyon
- Age
- 18 years and over
- People
- 150
- Run by
- GCS Ramsay Santé pour l'Enseignement et la Recherche
See details and how to joinNCT07274657 - Phase 3Active, not recruitingStudy Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
- Where
- Creteil Cedex, Lyon, Marseille, Paris, Rouen Cedex, Saint-Herblain, Toulon Cedex 9, Toulouse
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Amgen Inc.
See details and how to join2024-520050-38-00 - No phaseTaking peopleTARGETed Therapy Drug MONITOring in DIGestive Oncology
- Where
- Amiens, Auxerre, Avignon, Bayeux, Clermont-Ferrand, Clichy, Dijon, Évreux, Lille, Lyon, Marseille, Nancy, Nantes, Nice, Paris, Plérin, Poitiers, Reims, Rennes, Rouen, St-Malo, Strasbourg, Tours, Villejuif
- Age
- 18 years and over
- People
- 330
- Run by
- UNICANCER
See details and how to joinNCT05443087 - Phase 2CompletedDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Créteil, Marseille, Paris, Strasbourg Cedex, Villejuif
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00 - No phaseTaking peopleEvaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour
- Where
- Angers, Bordeaux, Caen, Lille, Lyon, Marseille, Montpellier, Nantes, Poitiers, Toulouse
- Age
- 18 years and over
- People
- 150
- Run by
- Institut Claudius Regaud
See details and how to joinNCT06876532 - Phase 1/2Not yet taking people in FranceA Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
- Where
- Marseille, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 262 worldwide
- Run by
- IDEAYA Biosciences
See details and how to joinNCT07174583 · EU 2025-523438-24-00 - Phase 2Taking peopleAssessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
- Where
- Angers, Bordeaux, Brest, Caen Cedex 5, Chambéry, Clermont-Ferrand, Clichy, Dijon, Grenoble Cedex 9, Lille Cedex, Lyon, Lyon Cedex 02, Marseille, Montpellier Cedex 5, Nantes, Nice Cedex 2, Paris, Paris Cedex 13, Pessac, Rouen, Rouen Cedex, St Etienne Cedex 2, St Herblain, Strasbourg Cedex, Toulouse, Vandoeuvre Les Nancy Cedex, Villejuif
- Age
- 18 years and over
- People
- 146
- Run by
- Institut du Cancer de Montpellier - Val d'Aurelle
See details and how to joinNCT04954820 · EU 2024-511001-28-00 - Phase 3Not yet taking people in FranceAdjuvant Trial in Pancreatic Neuroendocrine Tumors
- Where
- Villejuif
- Age
- 18 years and over
- People
- 300
- Run by
- Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07591493 - Phase 1/2SuspendedStudy Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
- Where
- Clichy, Nantes Cedex 1
- Age
- 18 years and over
- People
- 60
- Run by
- Nantes University Hospital
See details and how to joinNCT06735560 · EU 2023-508567-75-00 - Phase 3Taking peopleEfficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
- Where
- Bourdeaux, Dijon, Lille, Lyon, Marseille, Montpellier, Nantes, Paris
- Age
- 18 years and over
- People
- 170 worldwide
- Run by
- Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00 - Phase 2Taking peopleAssessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
- Where
- Amiens, Caen, Lille
- Age
- 18 years and over
- People
- 88
- Run by
- Centre Oscar Lambret
See details and how to joinNCT05500391 - Phase 3Taking peopleTarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)
- Where
- Angers, Avignon, Besançon, Boulogne, Caen, Chambray-lès-Tours, Dijon, Grenoble, Le Mans, Lille, Limoges, Lyon, Marseille, Montpellier, Nice, Paris, Pessac, Pierre-Bénite, Poitiers, Reims, Rennes, Rouen, Saint-Herblain, Strasbourg, Toulon, Toulouse, Tours, Vandœuvre-lès-Nancy, Villefranche-sur-Saône
- Age
- 18 years and over
- People
- 129
- Run by
- Intergroupe Francophone de Cancerologie Thoracique
See details and how to joinNCT06937905 - Phase 2Not yet taking people in FranceTrial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)
- Where
- Amiens, Bobigny, Caen, Clichy, Créteil, Dijon, Grenoble, Lille, Lyon, Marseille, Montpellier, Paris, Pessac, Poitiers, Reims, Rouen, Strasbourg, Villejuif
- Age
- 18 years and over
- People
- 122
- Run by
- Hospices Civils de Lyon
See details and how to joinNCT07337447 · EU 2024-519922-19-00 - Phase 2Taking peopleDostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
- Where
- Angers, Avignon, Besançon, Brest, Caen, Clermont-Ferrand, Créteil, Dijon, Lyon, Marseille, Nancy, Paris, Pessac, Poitiers, Reims, Rennes, Rouen, Saint-Herblain, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 120
- Run by
- UNICANCER
See details and how to joinNCT06333314 - Phase 2Taking peopleChemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
- Where
- Albi, Amiens, Angers, Antony, Auxerre, Avignon, Avignon Cedex 9, Bayonne, Besançon, Bobigny, Boulogne-sur-Mer, Caen Cedex 9, Cahors, Cergy Pontoise, Chalon Sur Saone, Chambéry, Chambray Les Tours, CHAMPIGNY SUR MARNE, Clermont-Ferrand, Clichy, Colmar Cedex, Corbeil Essonnes Cedex, Dijon, Fort De France Cedex, Grenoble, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Levallois-Perret, Lille Cedex, Limoges Cedex 1, Lorient, Lyon, Marseille, METZ, Mont-De-Marsan Cedex, Montpellier Cedex 5, Nantes, Nevers, Nice Cedex 2, Orléans, Orleans Cedex 2, Paris, Paris Cedex 12, Pau Cedex, Perpignan Cedex, Pessac, Plérin, Poitiers, PRINGY, Reims, Reims Cedex, Rennes Cedex 9, Rouen Cedex, Saint-Herblain Cedex, Saint-Malo, Saint-Priest-en-Jarez, Strasbourg, Tarbes, Thonon-Les-Bains, Toulouse Cedex 9, Troyes, Vandoeuvre Les Nancy_ Cedex, Vannes, Villejuif, Villeurbanne
- Age
- 18 years and over
- People
- 218
- Run by
- Centre Hospitalier Universitaire Dijon
See details and how to joinNCT04325425 · EU 2024-515300-39-00